SGMT (Sagimet Biosciences, Inc.) Earnings per share for the last four quarters

Sagimet (SGMT) - corporate logo

Sagimet Biosciences (SGMT) is building biochemical supply chains through a diversified network of laboratories, which protects business profitability. Historical price action, where EPS TTM stands at 33.70, correlates with the use of AI in molecular discovery and the automation of drug synthesis. Growth prospects are based on the denifanstat patent, which provides access to the high-margin metabolic steatohepatitis therapy segment.

SGMT sagimet.com Net earnings per share (EPS TTM) (11/23/2025 - 11/18/2026)

SGMT (Sagimet Biosciences): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:SGMT (Sagimet Biosciences, Inc.)
Core merchandise of Sagimet Biosciences Inc

The investment attractiveness of Sagimet Biosciences (SGMT) is driven by its success in treating metabolic liver pathologies and the scientific expertise of its management. This metric measures the annual dynamics of net income per share over twelve months, capturing the business's actual growth rate. Analyzing the rolling annual change in EPS allows investors to filter out market noise and identify overvaluation risks. The stability of this trend confirms the fundamental value of the company's capital.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS